Anebulo Pharmaceuticals (ANEB) Peer Comparison
$0.39
$0.08
(23.81%)
As on 03-Sep-2026 16:00EDT
Market cap
$13 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Edit
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
13 | 16,765 | 16,261 | 13,492 | 12,332 |
Revenue ($ Mln) |
-- | 2,782 | 1,054 | 2,436 | 1,284 |
Net Profit ($ Mln) |
-7.98 | 491.50 | 755.85 | 860.62 | -325.10 |
Net Margin (%) |
-- | 17.67 | 71.69 | 35.33 | -25.32 |
RoE (%) |
-81.44 | 110.09 | -- | 42.98 | -57.72 |
Price to Earnings |
-- | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
1.70 | 39.29 | 9.76 | 7.42 | 23.98 |
Income Statement ($ Mln)
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 2,530.23 | 691.71 | 2,320.13 | 958.40 |
|
Cost of Revenue
|
-- | 1,769.62 | 103.18 | 83.70 | 56.15 |
|
Gross Profit
|
-- | 760.62 | 588.53 | 2,236.43 | 902.26 |
|
Operating Expenses
|
9.22 | 225.68 | 719.42 | 1,364.24 | 1,202.35 |
|
Operating Profit (EBIT)
|
-9.22 | 534.94 | -130.89 | 872.19 | -300.10 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-8.48 | 542.38 | -204.26 | 941.21 | -288.28 |
|
Provision for Tax
|
-- | 91.25 | 14.78 | 158.64 | -465.89 |
|
Profit after Tax (Net Income)
|
-8.48 | 451.12 | -219.03 | 782.57 | -288.28 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
11.66 | 459.07 | -162.75 | 2,161.32 | 602.69 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.26 | 172.65 | 395.83 | 277.46 | 346.61 |
|
Current Liabilities
|
0.22 | 1,343.75 | 1,068.94 | 405.64 | 310.29 |
|
Total Liabilities
|
12.15 | 1,975.47 | 1,302.02 | 2,844.42 | 1,259.59 |
Assets ($ Mln)
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.18 | 985.85 | 193.50 | 1,401.13 | 13.82 |
|
Current Assets
|
11.96 | 989.62 | 1,108.51 | 1,443.29 | 1,245.77 |
|
Total Assets
|
12.15 | 1,975.47 | 1,302.02 | 2,844.42 | 1,259.59 |
|
Total Debt*
|
-- | 250.50 | 871.41 | 173.04 | 354.36 |
|
Net Current Assets
|
11.47 | -354.12 | 39.59 | 1,037.65 | 935.48 |
Cashflow ($ Mln)
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.35 | 713.22 | 51.77 | 884.27 | -189.55 |
|
Cash Flow from Investing Activities
|
-- | -31.14 | -8.15 | 350.44 | 32.32 |
|
Cash from Financing Activities
|
14.88 | -860.39 | 34.89 | -969.59 | 255.98 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-109.69 | 53.56 | -30.01 | 32.82 | -31.49 |
|
ROE (%)
|
-109.69 | 70.23 | 163.18 | 35.53 | -42.49 |
|
ROA (%)
|
-104.63 | 22.13 | -17.65 | 27.02 | -25.05 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 17.83 | -31.67 | 33.73 | -30.08 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.20 | 0.90 | 0.07 | 4.32 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-3.45 | 11.56 | 42.07 | 50.13 | 38.12 |
|
EPS Growth (%)
|
0.35 | 0.23 | 0.44 | 0.50 | 0.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-6.97 | 36.06 | -59.76 | 15.79 | -45.32 |
|
Price / Book Value
|
5.07 | 35.44 | -80.42 | 5.72 | 21.68 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-6.16 | 28.08 | -121.54 | 12.44 | -47.02 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | 0.55 | -5.35 | 0.08 | 0.59 |
|
Short term debt to equity ratio
|
-- | 0.05 | -2.99 | 0.01 | 0.00 |
|
Current Ratio
|
53.36 | 0.74 | 1.04 | 3.56 | 4.01 |
|
Quick Ratio
|
-- | -- | 0.76 | 3.50 | 3.77 |
|
Interest Coverage
|
-21.21 | 19.04 | -1.64 | -- | -11.92 |
Operating Efficiency Ratios
| Anebulo Pharmaceuticals (ANEB) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 15.89 | 22.79 | 12.37 | 14.03 |
|
Asset Turnover
|
0.00 | 1.24 | 0.56 | 0.80 | 0.83 |
|
Receivable days
|
-- | 50.42 | 85.52 | 43.48 | 35.88 |
|
Inventory Days
|
-- | 0.00 | 1,056.70 | 96.17 | 354.23 |
|
Payable days
|
-- | 6.26 | 331.01 | 147.97 | 300.79 |
|
Cash Conversion Cycle
|
-- | 43.41 | 811.21 | -8.32 | 89.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
